Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms

• Published in: Advanced science Vol. 10; no. 25; pp. e2206663 - n/a
• Main Authors: Chen, Xue, Ding, Jian‐cheng, Hu, Guo‐sheng, Shu, Xing‐yi, Liu, Yan, Du, Jun, Wen, Zi‐jing, Liu, Jun‐yi, Huang, Hai‐hua, Tang, Guo‐hui, Liu, Wen
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.09.2023; John Wiley and Sons Inc; Wiley
• Subjects: Breast cancer; Cancer therapies; Cell growth; Drug resistance; Endocrine therapy; Epigenetics; ER‐positive breast cancer; estrogen and estrogen receptor; Estrogens; Genes; Genomes; Homeostasis; lncRNA; Metastasis; Signal transduction; Tumors; Womens health; ER-positive breast cancer; estrogen and estrogen receptor; lncRNA
• ISSN: 2198-3844; 2198-3844
• DOI: 10.1002/advs.202206663

Endocrine therapy is the frontline treatment for estrogen receptor (ER) positive breast cancer patients. However, the primary and acquired resistance to endocrine therapy drugs remain as a major challenge in the clinic. Here, this work identifies an estrogen‐induced lncRNA, LINC02568, which is highl...